Abstract
Over the past few years, the 340B Drug Pricing Program has received increased scrutiny from Congress and the pharmaceutical industry. The Health Resources and Services Administration (HRSA) recently announced a renewed focus on making sure participants in the 340B program are adhering to specified policies and rules by conducting audits of covered entities. Audits allow HRSA and all stakeholders the opportunity to improve oversight, monitor for potential violations, prevent and detect diversions of the discount, and most importantly, share information and create compliance, said CDR Krista Pedley, PharmD, MS, Director of the HRSA Office of Pharmacy Affairs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
